Table 5.

Logistic regression analysis of related factors affecting ≥ grade 2 hepatic adverse reactions after SBRT treatment

Variables	β	SE	Wald	P-value	RR	95% CI
Sex	0.400	0.674	0.353	0.553	1.492	0.398–5.587
Age (years)	0.010	0.613	0.085	0.987	1.010	0.304–3.353
ECOG scale	0.477	1.197	0.159	0.690	1.611	0.154–16.842
History of hepatitis B	0.550	0.751	0.537	0.464	0.577	0.132–2.513
BCLC staging	0.203	0.733	0.077	0.782	0.816	0.194–3.433
Prior of TACE	0.076	0.843	0.008	0.929	1.078	0.207–5.267
GTV (mL)	0.298	0.833	0.128	0.721	1.347	0.263–6.899
Total liver volume (mL)	−1.806	0.665	7.388	0.007	0.164	0.045–0.604
Normal liver volume (mL)	−1.504	0.658	5.230	0.022	0.222	0.061–0.806
Number of lesions	1.453	0.837	3.011	0.083	4.257	0.829–22.057
Intrahepatic progression	0.083	0.722	0.013	0.908	0.920	0.223–3.790

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; RR, relative risk; SBRT, stereotactic body radiation therapy; SE, standard error; TACE, transarterial chemoembolization.